A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects
NCT ID: NCT03726866
Last Updated: 2018-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2018-08-31
2019-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Drug-drug Interaction of CKD-330 and D086
NCT03017950
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers
NCT05372380
Study to Compare the Safety and Pharmacokinetics of CKD-397
NCT02645890
Drug-drug Interaction Study (CKD-501, Ketoconazole)
NCT01330563
Pharmacokinetic Interaction Between AZD3480 and Donepezil
NCT00713765
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
Sequence 1
Sequence 1
D326, D337 or CKD-828 for 9 days
Sequence 2
Sequence 2
Sequence 2
D326, D337 or CKD-828 for 9 days
Sequence 3
Sequence 3
Sequence 3
D326, D337 or CKD-828 for 9 days
Sequence 4
Sequence 4
Sequence 4
D326, D337 or CKD-828 for 9 days
Sequence 5
Sequence 5
Sequence 5
D326, D337 or CKD-828 for 9 days
Sequence 6
Sequence 6
Sequence 6
D326, D337 or CKD-828 for 9 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sequence 1
D326, D337 or CKD-828 for 9 days
Sequence 2
D326, D337 or CKD-828 for 9 days
Sequence 3
D326, D337 or CKD-828 for 9 days
Sequence 4
D326, D337 or CKD-828 for 9 days
Sequence 5
D326, D337 or CKD-828 for 9 days
Sequence 6
D326, D337 or CKD-828 for 9 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Calculated body mass index(BMI) of ≥ 19 and ≤ 28kg/m²
3. Subject who agree to use a combination of effective contraceptive methods or medically acceptable contraceptive methods from the date of first administration of Investigational product until completion of the clinical trial
4. Subject who agree not to provide sperm
5. Subject who voluntarily agree to participate in this study
Exclusion Criteria
2. Subject who has a clinically significant disease or history such as endocrine, gastrointestinal, cardiovascular, muscular disease.
3. Genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose uptake disorder
4. Subject who have received other clinical trial drugs within 90 days prior to the screening visit
5. Any clinically significant active chronic disease
19 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyeong-Seok Lim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Pharmacology and Therapeutics / Asan Medical Center, University of Ulsan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center, University of Ulsan
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
186DDI18020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.